Workflow
Di Yi Cai Jing Zi Xun
icon
Search documents
恒生科技指数跌超4%,中兴通讯跌超12%,中芯国际跌超6%
Di Yi Cai Jing Zi Xun· 2025-10-17 08:41
截至10月17日收盘,恒指报25247.10点,跌2.48%,周跌3.97%;恒生科技指数报5760.38点,跌4.05%, 周跌7.98%。 中兴通讯跌超12%,华虹半导体跌近7%,中芯国际跌超6%;百度、阿里巴巴、美团均跌超4%,小米集 团、京东集团跌超3%;药捷安康涨超22%,周大福涨超5%。 编辑丨瑜见 | 代码 | 名称 | 现价 涨跌 | 涨跌幅 | | --- | --- | --- | --- | | HSI | 恒生指数 | 25247.10c -641.41 | -2.48% | | HSTECH 恒生科技 | | 5760.38c -243.18 | -4.05% | | HSBIO | 恒生生物科技 | 15783.20c -590.22 | -3.60% | | HSCEI | 恒生中国企业指数 | 9011.97 c -247.49 | -2.67% | | HSCI | 恒生综合指数 | 3894.61c -106.73 | -2.67% | ...
美股科技“七姐妹”盘前齐跌
Di Yi Cai Jing Zi Xun· 2025-10-17 08:28
此外,美国大型银行股盘前普跌,美国银行跌超3%,花旗集团跌1.7%,高盛、富国银行跌约1.4%,摩 根大通跌超1%。 编辑|钉钉 10月17日, 美股三大股指期货走低,截至发稿,均跌超1%。 美股科技"七姐妹"盘前普跌,微软跌0.9%,Meta、亚马逊、苹果、谷歌A跌1%,特斯拉、英伟达跌 2%。 中概股盘前普跌,携程、理想汽车、腾讯音乐跌2%,哔哩哔哩、拼多多、百度、阿里巴巴跌3%,蔚来 跌5%。 ...
良品铺子“不卖了”
Di Yi Cai Jing Zi Xun· 2025-10-17 08:09
Core Viewpoint - The control transfer of Liangpinpuzi has been terminated after three months of negotiations, with no change in the company's controlling shareholder or actual controllers [2][3]. Group 1: Control Transfer Details - On October 16, Liangpinpuzi announced the termination of the share transfer agreement with Changjiang Guotai, as the conditions for the agreement were not fully met by the deadline [2]. - The agreement involved the transfer of 72.23988 million shares (18.01% of total shares) from the controlling shareholder Ningbo Hanyi and 11.97012 million shares (2.99% of total shares) from its partner Liangpin Investment to Changjiang Guotai [2][3]. Group 2: Company Performance - Liangpinpuzi reported a revenue of 2.829 billion yuan for the first half of 2025, a year-on-year decrease of 27.21% [3]. - The net profit attributable to shareholders was -93.5531 million yuan, reflecting a significant decline of 491.59% year-on-year [3][4]. - The basic earnings per share were -0.24 yuan, marking a 500% decrease compared to the previous year [4].
近4800只个股下跌
Di Yi Cai Jing Zi Xun· 2025-10-17 07:37
2025.10.17 燃气板块逆势上涨,国新能源4天3板,长春燃气涨超6%,成都燃气、百川能源、天壕能源涨超5%。 沪深两市成交额1.94万亿,较上一个交易日放量69亿。全市场近4800只个股下跌。 10月17日,A股三大指数震荡下行。截至收盘,沪指跌1.95%,深证成指跌3.04%,创业板指跌3.36%。 资金流向 主力资金全天净流入贵金属、燃气、纺织服装等板块,净流出多元金融、旅游酒店、教育等板块。 具体到个股来看,中际旭创、N道生、东信和平获净流入17.14亿元、7.01亿元、6.44亿元。 净流出方面,比亚迪、中兴通讯、阳光电源遭抛售19.70亿元、18.92亿元、17.93亿元。 | 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | 000001 | 上证指数 | m | 3839.76 | -76.47 | -1.95% | | 399001 | 深证成指 | 1 | 12688.94 | -397.47 | -3.04% | | 399006 | 创业板指 | 1 | 2935.37 | -102.07 ...
万亿大消费增量当前,双11的逻辑彻底变了
Di Yi Cai Jing Zi Xun· 2025-10-17 07:05
今年双11,一个无法忽视的背景,正是外卖市场备受关注的变局。不仅颠覆了外卖本身,也让即时配送 突破餐饮场景,逐步渗透到品牌零售之中。 闪购为电商打开了庞大的增量空间,也带来了全新的挑战。在八月的阿里财报电话会上,"闪购与电商 的协同效应"被反复提及。对于淘宝来说,日订单量超越美团只能算是阶段性成果,真正的考验是通过 新场景,释放更持久的新增量,而双11无疑是检验闪购与电商生态协同效果的关键一役。 电商已经在极端低价和流量争夺中"卷"了两年,而短短八个月间,闪购市场已经初具规模。有券商预 测,到2030年,中国即时零售市场规模有望突破3万亿,在线上电商中的渗透率将从6%提升至15.7%。 届时,消费者在电商每花6块钱,就会有1块花在即时配送上面。 针对这种变化,阿里在今年6月提出了"大消费"的构想。CEO吴泳铭提到,购物与生活服务融合的大消 费平台,是"两大历史性战略机遇"之一。 10月16日,天猫双11发布会上,阿里巴巴中国电商事业群淘宝平台总裁谌伟业(花名:处端)表 示:"今年的双11是淘宝开启大消费平台的第一个双11……随着更多的消费场景打通,更多跨品类的消 费打通,我们拥有了高频连接消费者的机会,这是一 ...
A股中兴通讯跌停
Di Yi Cai Jing Zi Xun· 2025-10-17 06:52
10月17日午后,中兴通讯A股跌停,报48.64元/股,成交额达153亿元。 编辑|钉钉 港股方面,中兴通讯现跌超12%。 ...
港股热门科技股,集体下挫
Di Yi Cai Jing Zi Xun· 2025-10-17 06:46
Market Overview - The Hong Kong stock market opened lower and continued to decline, with the Hang Seng Index falling by 2% in the afternoon, and the Hang Seng Tech Index dropping by 3.3% [1] Technology Sector Performance - Major technology stocks in Hong Kong experienced significant declines, with ZTE Corporation falling over 12%, BYD Electronics and Horizon Robotics both down over 7%, SMIC down over 6%, and both Hua Hong Semiconductor and SenseTime also declining [3] Stock Price Movements - Notable stock price changes include: - BYD Electronics: Current price at 38.040, down 3.040, a decrease of 7.40% - Horizon Robotics: Current price at 8.130, down 0.630, a decrease of 7.19% - SMIC: Current price at 69.300, down 4.600, a decrease of 6.22% - SenseTime: Current price at 2.360, down 0.130, a decrease of 5.22% - ASMPT: Current price at 83.700, down 4.600, a decrease of 5.21% - Other notable declines include JD Health, Kingdee International, Sunny Optical Technology, and Kingsoft, all experiencing declines between 4.28% and 4.90% [4]
解码上海生物医药全链条创新生态——走进上海生物医药创新成果展
Di Yi Cai Jing Zi Xun· 2025-10-17 06:45
Core Insights - The Shanghai Biopharmaceutical Innovation Achievements Exhibition showcases the progress made during the "14th Five-Year Plan" period, emphasizing innovation-driven development and reform in the biopharmaceutical sector [1][2]. Group 1: Innovation and Achievements - Shanghai has approved a total of 30 domestic Class 1 innovative drugs and 45 domestic Class 3 innovative medical devices from 2021 to September 2025, demonstrating its leading position in drug and device innovation in China [2]. - The number of overseas licensing transactions (License-out) from Shanghai reached 38 in 2024, accounting for 35% of the national total, with transaction amounts reaching $30.7 billion, representing 47% of the national total [2]. - Shanghai's research output in top-tier journals has increased significantly, with 3 out of 12 papers in the "Best of Cell 2024" list published by Shanghai researchers, and a total of 127 papers published in four major medical journals from 2021 to 2024 [3]. Group 2: Policy and Reform - The exhibition highlights 14 policy regulations and special measures introduced during the "14th Five-Year Plan" to promote high-quality development in the biopharmaceutical sector, covering areas such as drug regulation, medical device innovation, and clinical trials [5]. - New policies, including the "Opinions on Supporting the Full-Chain Innovation Development of the Biopharmaceutical Industry," aim to enhance the policy framework and support for the biopharmaceutical sector [5]. Group 3: Industry Growth and Structure - The biopharmaceutical industry in Shanghai has grown from ¥761.71 billion in 2021 to ¥984.70 billion in 2024, with a compound annual growth rate of 8.94%, and is expected to exceed ¥1 trillion in 2025 [6]. - By the end of 2024, Shanghai had 2,183 biopharmaceutical enterprises, including 675 manufacturing, 569 service, and 939 wholesale enterprises, indicating a robust industry structure [6]. - Major multinational pharmaceutical companies have established headquarters or R&D centers in Shanghai, with 19 out of the top 20 global pharmaceutical and medical device companies present [6]. Group 4: Financial Support and Investment - Shanghai's biopharmaceutical companies have been active in IPOs, with 102 companies listed across A-shares, Hong Kong, and the US, and several more in the pipeline [7]. - The Shanghai State Investment Corporation established a biopharmaceutical industry mother fund with a total scale of ¥22.5 billion to support the development of the biopharmaceutical innovation ecosystem [7].
53度飞天茅台补贴价跌破1700元
Di Yi Cai Jing Zi Xun· 2025-10-17 05:41
2025.10.17 本文字数:2188,阅读时长大约4分钟 作者 |第一财经 栾立 和电商渠道合作,正成为白酒企业无法回避的话题。在2025年秋季糖酒会期间,白酒在电商渠道的机会 与冲突也是企业和专家讨论的热点之一。传统渠道销售下滑难止,酒企希望在爆火的电商渠道中寻找新 增量,但又担心日渐强势的电商低价竞争冲击市场。而今年"双十一"大促刚开场,部分电商平台茅台、 五粮液等名酒补贴后促销价格又创新低。 酒企重新审视电商渠道 随着酒业深度调整的持续,今年秋糖讨论最多的莫过于新形势下行业的新增长点在哪里,而过去被视 为"洪水猛兽"的电商则成为行业关注的重点。 这一态度变化的背后,是今年酒水消费的进一步下滑。上半年,国内主要酒业上市公司半年报都出现了 不同程度地降速甚至下滑,而在刚刚过去的"双节"旺季,市场情况也并不乐观。 秋糖期间,盛初集团董事长王朝成公布的调研数据显示,在市场剧烈分化下,今年中秋和国庆市场白酒 整体销售额下滑约25%,主要与团购和政务市场的大幅萎缩有关。王朝成认为,目前白酒需求已触及谷 底,但去库存仍待时日。 与线下疲软相比,线上电商平台的白酒销售增长强劲。中酒协信息显示,节前最后一个周末,美团 ...
遭证监会立案后,603300,公布股东增持消息
Di Yi Cai Jing Zi Xun· 2025-10-17 05:03
Group 1 - The core point of the news is that Hainan Huatie's major shareholders plan to increase their stakes in the company, indicating confidence in its future performance [1][3] - Hainan Huatie's controlling shareholder, Hainan Jinkong, plans to increase its holdings by an amount not less than 25 million yuan and not exceeding 50 million yuan within six months starting from October 17 [1] - The company's shareholder, director, and general manager, Hu Danfeng, also plans to increase his stake by an amount not less than 30 million yuan and not exceeding 50 million yuan within the same timeframe [1] Group 2 - On October 16, Hainan Huatie received a notice from the China Securities Regulatory Commission regarding an investigation for suspected violations of information disclosure laws [3] - Despite the investigation, the company stated that all its production and operational activities are proceeding normally and that it will actively cooperate with the regulatory body's investigation [3] - The company's stock price has recently declined by 9.45%, closing at 6.9 yuan per share, reflecting market reactions to the ongoing issues [4] Group 3 - Hainan Huatie has recently faced challenges, including the cancellation of a 3.7 billion yuan order and a shift from major shareholders reducing their stakes to increasing them, which has contributed to a downward trend in its stock price [6] - The company had previously announced a total of 6.67 billion yuan in orders related to its foray into computing power business, which it began to develop in May 2024 [6]